BioLineRx (BLRX) Total Debt (2021 - 2025)

BioLineRx has reported Total Debt over the past 5 years, most recently at $8.9 million for Q4 2025.

  • Quarterly results put Total Debt at $8.9 million for Q4 2025, down 33.47% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (down 33.47% YoY), and the annual figure for FY2025 was $8.9 million, down 33.47%.
  • Total Debt for Q4 2025 was $8.9 million at BioLineRx, down from $13.4 million in the prior quarter.
  • Over the last five years, Total Debt for BLRX hit a ceiling of $13.4 million in Q4 2024 and a floor of $2.8 million in Q4 2021.
  • Median Total Debt over the past 5 years was $9.8 million (2023), compared with a mean of $9.0 million.
  • Biggest five-year swings in Total Debt: soared 268.81% in 2022 and later tumbled 33.47% in 2025.
  • BioLineRx's Total Debt stood at $2.8 million in 2021, then soared by 268.81% to $10.2 million in 2022, then decreased by 3.88% to $9.8 million in 2023, then soared by 37.49% to $13.4 million in 2024, then tumbled by 33.47% to $8.9 million in 2025.
  • The last three reported values for Total Debt were $8.9 million (Q4 2025), $13.4 million (Q4 2024), and $9.8 million (Q4 2023) per Business Quant data.